Accessibility Menu
Translational Development Acquisition Corp. logo

Translational Development Acquisition Corp.(NASDAQ) TDACU

Market Cap$242.71MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2024)+26%
5 YearN/A
1 Year+21%
1 Month+9%
$12.57
+0.00%
+0.00Today
Translational Development Acquisition Corp. last closing stock price
MetricPriceDate
Last closeUSD 12.572026-08-25
Translational Development Acquisition Corp. stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 12.572026-08-17
1 month+8.83%USD 11.552026-07-16
3 month+5.54%USD 11.912026-05-27
Year to date+20.4%USD 10.442025-12-15
1 year+21.33%USD 10.362025-08-20
Since inception+25.57%USD 10.012024-12-23

Translational Development Acquisition Corp. Financials at a Glance

Market Cap

$242.71MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

$5.54M

EPS (TTM)

$0.25

P/E Ratio

49.59

Dividend

$0.00

Beta (Volatility)

0.18 (Low)

Price

$12.57

Volume

188

Open

$11.89

Previous Close

$12.57

Daily Range

$11.89 - $12.89

52-Week Range

$10.36 - $17.29

Estimated Earnings Date

Sep 30, 2025

TDACU News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Translational Development Acquisition Corp.

Translational Development Acquisition Corp. is a blank check company focused on identifying and completing a significant business combination, particularly in the oil, gas, and natural resources sectors within Eastern Europe. The company currently has no operational businesses and aims to leverage its resources to create value through strategic mergers or acquisitions.

Products and Services
  • Focus on mergers and acquisitions in the natural resources sector
  • Strategic partnerships with companies in Eastern Europe
  • Investment opportunities in oil and gas industries
Growth Outlook
  • Market capitalization of approximately $254 million indicates strong investor interest
  • Recent quarterly net income of $946,982 shows potential profitability
  • Strategic focus on Eastern Europe aligns with growing energy demands
Financial Highlights
  • Trailing twelve months (TTM) P/E ratio of 42.06 suggests growth potential
  • Cash and short-term investments of $85,877 provide liquidity for future investments
  • Quarterly net income increased from $1.33 million to $0.95 million in recent quarters
Translational Development Acquisition Corp. operates in a unique niche, targeting the oil and gas sectors in Eastern Europe, which may present significant growth opportunities. The company's recent financial performance indicates a positive trajectory, with a notable increase in net income over the last two quarters. The strong market capitalization reflects investor confidence, while the liquidity position allows for strategic investments. As the energy sector continues to evolve, Translational Development Acquisition Corp. is well-positioned to capitalize on emerging opportunities in the region.
AI Generated • Aug 27, 2026

Industry

Capital Markets

Sector

Financials

Employees

2

CEO

Michael B. Hoffman, MBA

Website

www.translational-development.com

Headquarters

New York City, NY 10028, US

TDACU Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

3.28%

Return on Capital

-0.54%

Return on Assets

3.52%

Earnings Yield

2.02%

Dividend Yield

0.00%

Payout Ratio

58.20%

Stock Overview

Market Cap

$242.71MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

19.31M

Volume

188

Avg. Volume

486.469

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$1.32M

EBITDA

-$1.32M

Operating Cash Flow

-$849.38K

Capital Expenditure

$0.00

Free Cash Flow

-$849.38K

Cash & ST Invst.

$85.88K

Total Debt

$1.10M

Translational Development Acquisition Corp. Performance Analysis

Translational Development Acquisition Corp. annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Translational Development Acquisition Corp. sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Q22026-06-30N/A
Translational Development Acquisition Corp. annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.00N/A
20232023-12-31USD -0.03920.0%
20242024-12-31USD -0.00-87.5%
20252025-12-31USD 0.29N/A
Translational Development Acquisition Corp. sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-308.0%
Q42025-12-31-9.0%
Q12026-03-31-16.5%
Q22026-06-30-27.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$242.71MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$121.36M

N/A

Employees

2

N/A

Net Income

$946.98K

-41.7%

EBITDA

-$661.05K

-198.9%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$85.88K

+143.6%

Total Debt

$1.10M

-79.2%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$1.10M

-79.2%

Return on Assets

3.52%

N/A

Return on Invested Capital

-0.85%

N/A

Free Cash Flow

-$338.75K

-97.7%

Operating Cash Flow

-$338.75K

-97.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
RTACRenatus Tactical Acquisition Corp I Class A Ordinary Shares
$10.48+0.29%
WLACWWillow Lane Acquisition Corp.
$8.34+203.27%
DMYYdMY Squared Technology Group, Inc.
$13.45+3.46%
FTIIFutureTech II Acquisition Corp.
$12.02+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About TDACU

What is the current price of Translational Development Acquisition Corp.?

Translational Development Acquisition Corp. is trading at $12.57 per share.

What is the 52-week range for Translational Development Acquisition Corp.?

Over the past 52 weeks, Translational Development Acquisition Corp. has traded between $10.36 and $17.29.

How much debt does Translational Development Acquisition Corp. have?

As of the most recent reporting period, Translational Development Acquisition Corp. reported total debt of $1.10M.

How much cash does Translational Development Acquisition Corp. have on hand?

Translational Development Acquisition Corp. reported $85.88K in cash and cash equivalents in its most recent financial results.

What is Translational Development Acquisition Corp.’s dividend yield?

Translational Development Acquisition Corp. does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services